Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant non-small-cell lung cancer, drawn from the whole corpus: 47 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to G12C inhibitors are shallower and shorter in lung cancer than EGFR or ALK inhibitors achieve, and no overall survival benefit over docetaxel has been shown.
Liver toxicity when a G12C inhibitor follows or accompanies a checkpoint inhibitor limits first-line combinations.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
STK11 and KEAP1 co-mutations predict poor outcome with every treatment and have no targeted therapy.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Resistance is polyclonal and mechanistically diverse, arguing for combinations from the start.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
KRAS G12C NSCLC after ≥1 line; 5 Jan 2024 (conditional)
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.